Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates

Pharmacogenetics

Volumn 12, Issue 8, 2002, Pages 635-645

  Sorich, Michael J ^a   Smith, Paul A ^b   McKinnon, Ross A ^a   Miners, John O ^b,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Pharmacophore; QSAR; UDP glucuronosyltransferase; UGT1A1

Indexed keywords

1 NAPHTHOL; 3 HYDROXYFLAVONE; 3,3',5' TRIIODOTHYRONINE; 4 HYDROXYBENZOIC ACID; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALIZARIN; ANTHRAFLAVIC ACID; BILIRUBIN; BUPRENORPHINE; ESTRADIOL; ETHINYLESTRADIOL; EUGENOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; HYMECROMONE; MORPHINE; NALTREXONE; NARINGENIN; PHENOLPHTHALEIN; QUERCETIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; GENOTYPE; METABOLISM; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; XENOBIOTIC METABOLISM;

GLUCURONOSYLTRANSFERASE; MODELS, BIOLOGICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 12244277451     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200211000-00008     Document Type: Article

References (41)

1. Miners JO, Mackenzie Pl, Drug glucuronidation in humans. Pharmacol Ther 1991; 51:347-369.
2. Mackenzie Pl, Owens IS, Burchell B, Beck KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7:255-269.
3. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie Pl. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31:817-899.
4. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Ann Rev Pharmacol Toxicol 2000; 40:581-616.
5. Miners JO, McKinnen RA, Mackenzie Pl. Genetic pelymerphism of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; in press.
6. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyl-transferase cDNAs with expression in COS-1 cells. J Biol Chem 1991; 266:1043-1047.
7. Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 1993; 43:649-654.
8. Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronesyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 1994; 303:233-240.
9. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphospho-glucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotype. Hum Mut 2000; 16:297-306.
10. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphism of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.
11. Zucker SD, Qin X, Rouster, Yu F, Green RM, Keshaven P, et al. Mechanism of indinivir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98:12671-12676.
12. Posner J, Cohen HF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's Syndrome). Br J Clin Pharmacol 1989; 28:117-120.
13. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wilkel JH, Wrighton SA. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999; 9:477-489.
14. Ekins S, De Groot MJ, Jones JP, Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 2001; 29:936-944.
15. Lewis DFV, Ioannides C, Parke DV. An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. Drug Metab Rev 1998; 30:709-737.
16. Todeschini R, Consonni V. Handbook of Molecular Descriptors. Weinheim: Wiley-VCH; 2000.
17. Livingstone DJ. The characterization of chemical structures using molecular properties. A survey. J Chem Inf Comput Sci 2000; 40:195-209.
18. Clement OO, Mehl AT. HipHop: Pharmacophores based on multiple common-feature alignments. In: Guner O, ed. Pharmacophore Perception, Development, And Use in Drug Design. La Jolla: International University Line; 2000. pp, 69-84.
19. Schafferhans A, Klebe G. Docking ligands onto binding site representations derived from proteins built by homology modeling. J Mol Biol 2001; 307:407-427.
20. Martin YC, Kim KH, Lin CT. Comparative molecular field analysis: CoMFA. In: Charton M, ed. Advances in Quantitative Structure-property Relationships, vol. 1. Greenwich: Jai Press Inc; 1996. pp. 1-52.
21. King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, Tephly TR. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 1996; 332:92-100.
22. Visser TJ, Kaptein E, Gijzel AL, de Herder WW, Ebner T, Burchell B. Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronosyltransferase isoenzymes. FEBS Lett 1993; 324:358-360.
23. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
24. King CD, Rios GR, Green MD, Mackenzie PI, Tephly TR. Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. Drug Metab Dispos 1997; 25:251-255.
25. Miners JO, Lillywhite KJ, Matthews AP, Jones ME, Birkett DJ. Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. Biochem Pharmacol 1988; 37:665-671.
26. Ekins S, Ring BJ, Bravi G, Winkel JH, Wrighton SA. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium. In: Guner, ed. Pharmacophore perception, development, and Use in drug design. La Jolla: International University Line; 2000, pp. 270-299.
27. Sprague PW, Automated chemical hypothesis generation and database searching with catalyst. Perspect Drug Discov Des 1995; 3:1-20.
28. Barnum D, Greene J, Smellie A, Sprague P. Identification of common functional configurations among molecules. J Chem Inf Comput Sci 1996; 36:563-571.
29. Robinson DD, Winn PJ, Lyne PD, Richards G. Self-organizing molecular field analysis: A tool for structure-activity studies. J Med Chem 1999; 42:573-583.
30. Cramer RD III, Patterson DE, Bunce JD, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988; 110:5959-6967.
31. Good AC, So S, Richards G, Structure-activity relationships from molecular similarity matrices. J Med Chem 1993; 36:433-438.
32. Whitley DC, Ford MG, Livingstone DJ. Unsupervised forward selection: A method for eliminating redundant variables. J Chem Inf Comput Sci 2000; 40:1160-1168.
33. Wold S, Ruhe A, Wold H, Dunn WJ III. The collinear problem in linear regression. The partial least squares (PLS) approach to generalized inverses. Siam J Sci Stat Comput 1984; 5:735-743.
34. Ekins S, Bravi G, Wikel JH, Wrighton SA. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 1999; 291:424-433.
35. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, Vandenbranden M, et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther 1999; 288:21-29.
36. Resetar A, Minick D, Spector T. Glucuronidation of 3′-azido-3′-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol 1991; 42:559-568.
37. Yin H, Bennett G, Jones JP. Mechanistic studies of uridine diphosphate glucuronosyltransferase. Chem Biol Interact 1994; 90:47-58.
38. Kim KH. Quantitative structure-activity relationships of the metabolism of drugs by uridine diphosphate glucuronosyltransferase. J Pharm Sci 1991; 80:966-970.
39. Klebe G, Abraham U, Mietzner T, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994; 37:4130-4146.
40. Said M, Ziegler J, Magdalou J. Inhibition of bilirubin UDP-glucuronosyltransferase: A comparative molecular field analysis (CoMFA). Quant Struct-Act Relat 1996; 15:382-388.
41. Cupid BC, Holmes E, Wilson ID, Lindon JC, Nicholson JK. Quantitative structure-metabolism relationships (QSMR) using computational chemistry: Pattern recognition analysis and statistical prediction of phase II conjugation reactions of substituted benzoic acids in the rat. Xenobiotica 1999; 29:27-42.